Q&A with Gilles Cottier, SAFC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Q&A with Gilles Cottier, SAFC
A Q&A with Gilles Cottier, president of SAFC, on recent industry trends.

Pharmaceutical Technology
Volume 36, Issue 1, pp. 81

PharmTech:



What is the biggest industry challenge you're now facing?

Cottier:

While companies always feel pressure to compete on pricing, the real pressure in the market comes as a result of the drive to provide and guarantee quality through process improvements and robust supply-chain security. Over the past few years, the market has seen a paradigm shift toward quality and supply-chain integrity. Demand to increase GMP compliance originated with regulatory bodies, but has been further emphasized by requests for compliance from customers and the industry as a whole. This shift in focus highlighted many issues, such as contamination, counterfeiting, and falsified documentation of pharmaceuticals and ingredients. The industry responded with a focus on accountability and a commitment to rectifying these matters and ensuring that offenders were held liable for their actions. It was encouraging to see the industry come together as a community to demand better quality for customers and, subsequently, the end-patient population. However, with these demands come pressures on suppliers and CMOs to meet these increasing quality requirements while keeping costs reasonable for customers.

PharmTech:

Do you see a new industry trend emerging?

Cottier:

As we continue to emerge from the economic downturn of the past couple of years, our industry as a whole has been forced to re-examine the way it does business. We have seen an increased focus on supply-chain transparency and quality. This problem has yet to be solved entirely, and the industry as a whole needs to continue to address it. Some companies offer increased transparency, but are still searching for cost–effective solutions. Transparency remains one of the major hurdles that the industry has yet to overcome.

Beyond that, the industry has been looking toward emerging markets and developing strategies to maximize market potential and positioning. SAFC has maintained a focus on identifying and participating in emerging markets to ensure that we are well-positioned to serve them.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here